UPDATE - UBS Initiates Coverage on BioMarin (BMRN) with a Buy; Accumulate on Pullback
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $90.07 --0%
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Join SI Premium – FREE
UPDATE - UBS initiates coverage on BioMarin (Nasdaq: BMRN) with a Buy. PT $43.
Analyst, Matthew Harrison, said, "We like the orphan disease model and the lack of generic cliffs. We believe BioMarin’s base value is ~$24 with ~$9/share in the stock for its key pipeline program GALNS. We are positive on GALNS and see solid data in 4Q12 driving the stock toward our target as risk-adjustments come down. Further, pipeline success on Pompe and PEG-PAL (not in our model) could add $3 each with positive 2H12 data. Mgt. has a deep pipeline behind these three late-stage assets and we see financial leverage and multiple expansion driving the stock in 2012."
To see more ratings on BMRN, Click Here
Analyst, Matthew Harrison, said, "We like the orphan disease model and the lack of generic cliffs. We believe BioMarin’s base value is ~$24 with ~$9/share in the stock for its key pipeline program GALNS. We are positive on GALNS and see solid data in 4Q12 driving the stock toward our target as risk-adjustments come down. Further, pipeline success on Pompe and PEG-PAL (not in our model) could add $3 each with positive 2H12 data. Mgt. has a deep pipeline behind these three late-stage assets and we see financial leverage and multiple expansion driving the stock in 2012."
To see more ratings on BMRN, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Starts Inspire Medical Systems (INSP) at Outperform
- Truist Securities Assumes BioMarin Pharmaceutical Inc. (BMRN) at Buy
- B.Riley Starts Energy Fuels (UUUU) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
